Global Tumor Ablation Market By Technology (Radiofrequency Ablation, Microwave Ablation, , and Other Ablation Technologies), By Treatment (Surgical Ablation, Laparoscopic Ablation, and Percutaneous Ablation), By Application (Kidney Cancer, Liver Cancer, Breast Cancer, and Other Cancers), and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032.

Tumor Ablation Market Overview:

The global tumor ablation market was worth USD 1,050 million in 2021. It is projected to grow at a CAGR of 14.9% between 2023 and 2032.

Major factors driving the market’s growth are the rising incidence of cancer and the high demand for safer treatments. The WHO estimates that between 10 and 11 million new cases of cancer will be diagnosed annually by 2032. From 2023 to 2032, the number of new cases of cancer is expected to rise by more than 80% in low-income countries. This compares to a 40% increase in high-income nations (40%). The market will be driven by the potential for growth in therapeutic options that are currently available and the high demand for non-invasive and minimally invasive therapies.

Global Tumor Ablation Market Scope:

Technology Analysis

In 2021, the radiofrequency tumor ablation segment had the highest revenue share of 35.0%. Radiofrequency tumor ablation technology was the most dominant segment in 2021.

Radiofrequency ablation has many advantages, including its efficiency and specificity in solid tumor removal procedures in the liver or kidneys. Multiple electrodes can be placed at different locations to increase procedural efficiency. Radiofrequency ablation is also used to treat multiple types of cancer simultaneously. This will improve the acceptance rate of advanced techniques for tumor ablation.

The rate of success of radiofrequency/microwave ablation technology in eliminating small liver tumors is attributed to being greater than 85%. The NCBI report found that patients who had surgery to remove tumors had a recurrence rate of between 30% and 70%. Radiofrequency ablation of similar tumors results in tumor recurrence at 0.7-8%. Market growth is expected to be driven by radiofrequency treatments to treat tumors early in their development.

Over the forecast period, microwave ablation technology will experience remunerative growth. The electromagnetic field created by the microwave (MW-) ablation device creates an electromagnetic field unlike the electric current generated by a radiofrequency device. This allows microwave treatment to be used in tissues that have low electrical conductance (bones or lungs).

This technology has significant benefits such as a larger tumor ablation volume; consistent high temperature, low discomfort ablation; and optimal heating for the cystic tissue. These benefits will drive the segment’s expansion. Its shorter procedure times (5-10 min), improved efficacy, and minimal complications, as well as shorter hospital stays, are expected to drive segment growth.

Treatment Analysis

In 2021, surgical ablation accounted for the highest revenue share at over 35.0%. The segment’s growth is expected to be driven by the increased incidence of breast and liver cancers and the inability to access advanced tumor ablation techniques. Over the forecast period, percutaneous ablation is expected to grow in value. These procedures are safer, faster, and leave you with less scarring. The segment is expected to grow because of factors like cost-efficiency, quick surgery times, and patient comfort, as well as cost-efficiency. The system’s growth will be limited by higher complications, particularly in hospitals that lack skilled personnel.

Percutaneous ablations aren’t possible in 25-55% of patients, according to the NCBI report. This is due to unfavorable locations. Percutaneous ablation has a higher rate of tumor recurrence due to the insufficient ablation of tumors deep within the tissue.

Percutaneous ablation should not be used to treat lesions located near the gall bladder, heart, bile conduit, and gastrointestinal tract. This is due to the risk of tumor recurrence. In such cases, laparoscopic surgery is able to provide long-term results while retaining minimal invasiveness. This will increase laparoscopic ablation’s growth over the forecast period.

Application Analysis

With a revenue share exceeding 20.0%, liver cancer dominated the market for 2021. This is due to the increasing incidence of primary and bile duct cancers. The market can be divided into five segments based on their application: kidney cancer (liver cancer), breast cancer (lung cancer), prostate cancer, and others. Other cancers include bone metastasis, ENT, and other types. Market growth is expected to be facilitated by the availability of advanced techniques and an increased incidence of cancer.

The forecast period will see a significant increase in kidney and renal cancer. The treatment of renal tumors can be done using radiofrequency or microwave ablation. Ablation of kidney tumors is possible in patients with solitary kidneys and tumors less than 4 cm.

Patients also need to have a slow recovery rate after surgery. According to the American Cancer Society, 79,000 cases of kidney cancer will be diagnosed in 2022. The demand for treatment procedures will increase due to the increased use of medical imaging.

The forecast period predicts that the market for lung tumor treatment will grow rapidly. The increasing incidence of this disease can explain why. Lung cancer was responsible for almost 11.6% of new cases of cancer in 2018. Non-Small Cell Lung Cancer (NSCLC), however, accounted for 85%. Market growth is expected to be accelerated by radiofrequency ablation, which is widely used in the treatment of NSCL.

Key Market Segments

Technology:

•  Radiofrequency Ablation
•  Microwave Ablation
•  Cryoablation
•  Irreversible Electroporation Ablation
•  Other Ablation Technologies

Treatment:

•  Surgical Ablation
•  Laparoscopic Ablation
•  Percutaneous Ablation

Application

•  Kidney Cancer
•  Liver Cancer
•  Breast Cancer
•  Lung Cancer
•  Prostate Cancer
•  Other Cancers

Market Dynamics

Patients and surgeons are increasingly inclined to minimally invasive procedures due to their speedy recovery, patient comfort, and shorter turnaround times. These factors will drive demand for advanced tumor ablation techniques in the future. Advanced tumor ablation can be performed outpatient and does not require hospital admission. This significantly reduces healthcare costs. For smaller tumors, ablative surgery is the best option. Its procedural volume is therefore indirectly dependent upon the annual cancer screening rates. Due to fewer screening efforts by authorities, the market suffered a significant impact in 2020.

A report from the Our World in Data (OWD), a Global Change Data Lab project, shows that over 70% of all cancer cases were caused by people over 50 in 2017. This number will rise in proportion to the growing geriatric population.

Noninvasive ablation is most popular among the aging population. As the body’s biological functions become compromised, the aging population is the primary target population. The rapidly growing aging population will increase the demand for tumor-ablation techniques over the forecast period.

Market players are constantly looking for new technologies to improve accuracy, portability, cost-effectiveness, and other factors that will drive them to launch innovative devices. These technological advances include image-guided equipment (HIFU), cryoablation, and image-guided equipment.

One of the new techniques to expand the market is the use of cooled radiofrequency denervation with internal cooled radiofrequency probes. This technique allows complete denervation at the sacroiliac joints, which aids in pain management.

Regional Analysis

North America was the dominant market, with a revenue share exceeding 30.0% by 2021. The growth of the region is due to a variety of factors, including government support for quality healthcare, high buying power parity, and availability of reimbursements.

The Patient Protection and Affordable Care Act (PPACA), which is a U.S. law that promotes quality and affordability in health care, and reduces healthcare costs for both individuals and the government, is an example. The precision medicine initiative, which creates tailored strategies for specific diseases, is another key growth factor. These government initiatives are expected to boost market growth and improve the overall healthcare system.

In 2021, Europe held a significant revenue share. This growth was due to a greater amount of public funding for Europe’s healthcare system. The market growth is expected to be boosted by the increasing geriatric population and government support for cancer control. The European Cancer Observatory, for instance, aims to raise awareness about cancer and early diagnosis techniques. It also offers advanced, minimally invasive treatment options.

The fastest-growing region in the forecast period is the Asia Pacific. Opportunities for growth are open to the expanding patient population and the increasing presence of healthcare providers in fast-developing economies like India and China. Healthcare utilization in the Asia Pacific is also improving with government assistance.

The Health Minister Cancer Patient Fund (HMCPF), which is administered by the Indian government, provides financial assistance to poor patients with cancer. This will fuel the region’s demand for tumor ablation equipment over the forecast period.

Кеу Regions and Countries Covered іn thе Report:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Key Companies & Market share Insights:

In 2021, Europe held a significant revenue share. This growth was due to a greater amount of public funding for Europe’s healthcare system. The market growth is expected to be boosted by the increasing geriatric population and government support for cancer control. The European Cancer Observatory, for instance, aims to raise awareness about cancer and early diagnosis techniques. It also offers advanced, minimally invasive treatment options.

The fastest-growing region in the coming years is the Asia Pacific. Opportunities for growth are open to the increasing patient population and the increasing presence of healthcare providers in fast-developing economies such as India and China.

The Healthcare sector in the Asia Pacific is also improving with government assistance. The scheme named, Health Minister Cancer Patient Fund (HMCPF), which is administered by the Indian government, provides financial assistance to poor patients with cancer. This will fuel the region’s demand for tumor ablation equipment over the foreseeable future.

Кеу Маrkеt Рlауеrѕ Included іn thе Report:

•  Angiodynamics (Covidien)
•  Boston Scientific Corporation
•  Medtronic Plc
•  Ethicon, Inc.
•  Galil Medical Inc.
•  Misonix Inc.
•  HealthTronics
•  Mermaid Medical
•  Theraclion
•  Chongqing Haifu Medical Technology Co. Ltd.
•  HS Hospital Service S.P.A
•  EDAP TMS S.A.
•  Other Key Players

For the Tumor Ablation Market research study, the following years have been considered to estimate the market size: